Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre J Issa

Showing results (161-170 of 204) with videos related to

Pageof 21
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 25, 2017
Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON ConsortiumReka Toth, Dominique Scherer, Linda E Kelemen, et al.
Blood|June 29, 2007
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeAndres O Soriano, Hui Yang, Stefan Faderl, et al.
Genome Research|August 19, 2010
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancerMarcos R H Estécio, Juan Gallegos, Céline Vallot, et al.
Cancer Research|May 19, 2006
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemiaAllen S Yang, Ketan D Doshi, Sang-Woon Choi, et al.
Toxicology and Applied Pharmacology|December 30, 2015
Zebrafish embryos as a screen for DNA methylation modifications after compound exposureManon C Bouwmeester, Sander Ruiter, Tobias Lommelaars, et al.
Cancer|March 15, 2006
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyHagop Kantarjian, Jean-Pierre J Issa, Craig S Rosenfeld, et al.
Journal of the National Cancer Institute|September 22, 2005
MGMT promoter methylation and field defect in sporadic colorectal cancerLanlan Shen, Yutaka Kondo, Gary L Rosner, et al.
Clinical Epigenetics|March 26, 2015
Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapyApostolia M Tsimberidou, Rabih Said, Kirk Culotta, et al.
Cancer Research|May 15, 2015
TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic LeukemiaJumpei Yamazaki, Jaroslav Jelinek, Yue Lu, et al.
Carcinogenesis|July 30, 2009
IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotypeHiromu Suzuki, Shinichi Igarashi, Masanori Nojima, et al.
Pageof 21

Showing results (161-170 of 204) with videos related to

Sort By:
Pageof 21
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 25, 2017
Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON ConsortiumReka Toth, Dominique Scherer, Linda E Kelemen, et al.
Blood|June 29, 2007
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeAndres O Soriano, Hui Yang, Stefan Faderl, et al.
Genome Research|August 19, 2010
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancerMarcos R H Estécio, Juan Gallegos, Céline Vallot, et al.
Cancer Research|May 19, 2006
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemiaAllen S Yang, Ketan D Doshi, Sang-Woon Choi, et al.
Toxicology and Applied Pharmacology|December 30, 2015
Zebrafish embryos as a screen for DNA methylation modifications after compound exposureManon C Bouwmeester, Sander Ruiter, Tobias Lommelaars, et al.
Cancer|March 15, 2006
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyHagop Kantarjian, Jean-Pierre J Issa, Craig S Rosenfeld, et al.
Journal of the National Cancer Institute|September 22, 2005
MGMT promoter methylation and field defect in sporadic colorectal cancerLanlan Shen, Yutaka Kondo, Gary L Rosner, et al.
Clinical Epigenetics|March 26, 2015
Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapyApostolia M Tsimberidou, Rabih Said, Kirk Culotta, et al.
Cancer Research|May 15, 2015
TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic LeukemiaJumpei Yamazaki, Jaroslav Jelinek, Yue Lu, et al.
Carcinogenesis|July 30, 2009
IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotypeHiromu Suzuki, Shinichi Igarashi, Masanori Nojima, et al.
Pageof 21